|
3rd International AIDS Society Conference on HIV Pathogenesis and TreatmentRio de Janeiro - July 24 - 27, 2005 |
IMMUNE MODULATION IN HAART-NAÏVE, ASYMPTOMATIC HIV-INFECTED INDIVIDUALS UNDERGOING THERAPEUTIC VACCINATION WITH HIV-1 WHOLE KILLED VACCINE
IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. TuOa0102
Gori A.1, Trabattoni D.2, Rizzardini G.3, Maserati R.4, Schenal M.2, Fasano F.2, Mazzotta F.5, Theofan G.6, Bray D.H.7, Clerici M.2
1Institute of Infectious Diseases and Tropical Medicine, "L. Sacco" Hospital, Milano, Italy, 2Chair of Immunology, University of Milano, Milano, Italy, 3H. di Circolo, Busto Arsizio (VA), Italy, 4H S Matteo IRCCS, Pavia, Italy, 5H. SS Annunziata, Firenze, Italy, 6The Immune Response Corporation, Carlsbad, CA 92008, United States of America, 7Medical Research Council Clinical Trials Unit, London, United Kingdom
INTRODUCTION: Use of agents that enhance HIV-specific immune responses with the goal of delaying initiation of antiretroviral therapy is being considered in HIV infection. Immunogenicity of a gp120-depleted, whole-killed HIV-1 vaccine consisting of HIV-1 antigen in Incomplete Freund«s Adjuvant (IFA) (REMUNE®), was assessed in antiretroviral-naïve HIV-1 infected subjects.
METHODS: HAART-naïve asymptomatic subjects with HIV-1 RNA 10,000-40,000 copies/mL and CD4 counts 400-800 cells/ml received three injections of REMUNE (n=19), IFA (n=11), or saline (n=10) at weeks 0, 12, and 24. Immunovirologic parameters were evaluated at these three times and 4 weeks after the last injection (wk 28).
RESULTS: Median absolute CD4 counts remained stable through week 28 in the REMUNE subjects, but declined both in saline and IFA treated subjects. Stabilization of CD4 counts in Remune patients was associated with increases in serum IL-7 and in naïve (CCR7+/RA+) CD4 T cells seen in REMUNE-treated individuals. In contrast, effector memory (EM: CCR7-/RA-) CD4 T cells were diminished at week in 28 in subjects that received REMUNE. IL-7 is required for thymopoiesis resulting in the generation of naïve T cells and is augmented during T cell reconstitution. The augmented serum concentration of IL-7 observed in Remune-treated patients suggests that thymic function is positively modulated by this immunomodulatory agent.
CONCLUSIONS: Immunotherapy with REMUNE is associated with changes in circulating lymphocytes phenotype and, possibly, with a positive effect on thymic functions. Data from larger cohorts of subjects are required to assess clinical significance of these observations.
Download PDF of this abstract.
050724
Basic | TuOa0102 | Andrea Gori
13.2 507 13.2 Therapeutic vaccination
Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.
AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.